Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures occur in 3050% of patients with GIO. Therefore, treatment of this disease is critical. Although patients should receive supplemental calcium and vitamin D, additional measures are necessary to prevent fractures. Estrogens and androgens may be of value in patients with hypogonadism, but bisphosphonates and teriparatide are the most effective agents in the treatment of GIO. Bisphosphonates prevent the early bone loss that follows exposure to glucocorticoids, and which has been attributed to increased resorption. Teriparatide appears to be more effective than alendronate in established GIO when reduced bone formation is the predominant pathophysiological mechanism. In conclusion, GIO can be prevented and treated with appropriate medical intervention.
Introduction
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis [Mazziotti et al. 2006 ]. This is because of the widespread use of glucocorticoids in a variety of clinical disorders, including autoimmune and inflammatory diseases, malignancies, and in patients undergoing organ transplantation. Patients exposed to glucocorticoids experience an early loss of bone mineral density (BMD) possibly because of increased bone resorption. Eventually, however, they enter a state of decreased bone remodeling due to direct suppressive effects of glucocorticoids on bone forming cells [Canalis et al. 2007a ]. The incidence of fractures in GIO is as high as 3050%. Therefore, it is important to consider appropriate therapeutic measures for this condition [Compston, 2007; Anon, 2001; Eastell et al. 1998 ].
The American College of Rheumatology (ACR) and the Royal College of Physicians (RCP) advocate the following measures for the prevention and treatment of GIO: general health awareness, administration of sufficient calcium and vitamin D, use of the minimal effective dose of corticosteroids and, when indicated, therapeutic intervention with bisphosphonates and other agents [Compston, 2007; Anon, 2001; Eastell et al. 1998 ]. Prevention is considered in patients exposed to glucocorticoids for 3 months and therapy in individuals exposed to glucocorticoids for !6 months.
The RCP guidelines suggest that treatment in GIO is indicated in the following groups:
(1) patients who are at high risk of osteoporosis, such as those taking prednisone-equivalent doses higher than 7.5 mg daily, or those with a personal history of fractures or those with lifestyle risk factors for osteoporosis, (2) patients with low risk of osteoporosis but with T-scores below À1.5 SD, as assessed by vertebral dual energy X-ray absorptiometry (DXA), (3) patients with low risk of osteoporosis and T-score above À1.5 SD, but with a decline in vertebral BMD of at least four per cent after one year of glucocorticoid treatment [Eastell et al. 1998 ].
The ACR recommends prevention in patients exposed to glucocorticoids for !3 months at doses !5 mg prednisone equivalents daily [Anon, 2001] . It recommends lifestyle changes, such as tobacco cessation and reduction of alcohol consumption, an exercise program, restriction of sodium intake (in the presence of hypercalciuria), sufficient calcium intake and adequate vitamin D supplementation [Compston, 2007] . It also recommends the use of bisphosphonates for the prevention and treatment of GIO. Treatment should be initiated in all individuals who start glucocorticoid treatment and in those on chronic glucocorticoid treatment whose T-score is À1.0, as assessed by DXA. Despite the clarity of these guidelines, it would appear that many clinicians do not follow them. In clinical practice, treatment with bisphosphonates seems to be based, most often, on low BMD, whereas these drugs are rarely prescribed for the prevention of GIO [Guzman-Clark et al. 2007 ]. The designation and selection of patients for preventative and therapeutic measures are somewhat arbitrary and controversial. A recent cost-effectiveness analysis demonstrated that treatment of GIO is cost effective in patients with a prior fracture, in individuals !75 years of age or in younger subjects with T-scores À2.0 [Kanis et al. 2007 ]. The elderly have reduced life-expectancy, as assessed by the Quality-Adjusted Life Years model, and cost effectiveness of treatment may be low. The economic reasoning should be tempered by the ethical imperative that the patient should be treated when treatment is indicated [Van Staa et al. 2007; Harris, 1987] .
Various pharmacological agents have been assessed for the prevention and treatment of GIO. In most studies, the primary endpoint was a change in BMD; fracture outcomes were measured in selected studies as secondary endpoints [Manelli and Giustina, 2000] .
Calcium and vitamin D Glucocorticoids decrease calcium absorption from the gastrointestinal tract, by opposing the actions of vitamin D, and by decreasing the expression of specific calcium channels in the duodenum [Huybers et al. 2007; Mazziotti et al. 2006 ]. In addition, renal tubular calcium reabsorption is inhibited by glucocorticoids, leading to hypercalciuria and calcium loss [Mazziotti et al. 2006 ].
Vitamin D and calcium supplementation are recommended by the ACR in subjects exposed to glucocorticoids [Anon, 2001] and vitamin D and its analogues prevent bone loss during glucocorticoid therapy and restoration of serum calcium [Boonen et al. 2006; Shiraishi et al. 2000; Schacht, 1999] . Vitamin D increases the intestinal absorption of calcium and its reabsorption in the distal renal tubule leading to higher serum calcium levels. In addition to its role in calcium homeostasis, vitamin D may also increase muscle strength [Amin et al. 2002] . In a 2-year randomized trial, patients with rheumatoid arthritis receiving prednisone therapy (mean dose 5.6 mg/day) exhibited a decline in BMD of 2.0 and 0.9% per year in the lumbar spine and trochanter, respectively [Buckley et al. 1996] .
Patients randomized to calcium (1000 mg/day) and vitamin D (500 IU/day) gained BMD at an annual rate of 0.72% at the spine and 0.85% in the trochanter [Buckley et al. 1996] . It is important to note that patients receiving glucocorticoids may display vitamin D resistance. Consequently, patients should receive sufficient vitamin D to maintain their 25-hydroxyvitamin D level substantially higher than the minimal, normal level of 30 ng/mL. Many experts recommend that the 25-hydroxyvitamin D level be maintained at ! 40 gg/ml or 110 nmol/L [Heaney, 2005] . Amounts of vitamin D to reach this goal are often between 1,000 and 2,000 IUs daily or the equivalent in weekly dosing.
Hormonal replacement therapy GIO can be associated with suppressed gonadal function in men and women since glucocorticoids inhibit gonadotropin release and as a consequence estrogen and androgen synthesis [Mazziotti et al. 2006 ]. This suppression of gonadal function may play a role in the pathogenesis of GIO [Canalis et al. 2007 ]. Moreover, estrogens seem to have protective effects on bone cells exposed to glucocorticoids [Gu et al. 2005 ]. In men with GIO, testosterone administered intramuscularly induced a significant increase in lumbar BMD, without any significant effects on BMD at femoral neck [Tracz et al. 2006 ]. The studies had a change in BMD as the primary endpoint, and no information on fractures is available [Hall et al. 1996; Reid et al. 1996] . Testosterone was also shown to improve muscular performance and quality of life in men with GIO [Crawford et al. 2003 ]. Therefore, treatment of hypogonadism in both men and women may prove beneficial in the management of GIO, if there are no medical contraindications to hormone replacement therapy.
Antiresorptive therapy
Following glucocorticoid exposure, there is an initial loss of bone, which is due to increased bone resorption [Mazziotti et al. 2006 ]. In view of this initial action of glucocorticoids, antiresorptive therapy was tested and shown to be effective in the prevention and treatment of GIO.
Thus, bisphosphonates are currently the major class of drugs used for GIO, in addition to their primary role in the treatment of postmenopausal osteoporosis. The bisphosphonates that have been approved for the treatment of GIO include alendronate, risedronate, and zoledronic acid.
Bisphosphonates are stable analogues of naturally occurring inorganic pyrophosphate. Stability is conferred by a carbon atom replacing the oxygen atom that connects two phosphate groups. The R1 and R2 side chains attached to the carbon atom are responsible for the wide spectrum of activity observed among bisphosphonates. R1 substitutions, such as a hydroxyl or amino group enhance the adsorption of the bisphosphonate to mineral, whereas the R2 substituents help to account for antiresorptive potency [Russell et al. 2008; Van Beek et al. 1996 ]. The different antiresorptive potency observed with different R2 groups is linked to their ability to inhibit farnesyl pyrophosphate synthase and to bind to hydroxyapatite [Nancollas et al. 2006 ].
Currently, bisphosphonates are considered to be the gold standard for the prevention and treatment of GIO [Canalis et al. 2007a [Canalis et al. , 2007b Compston, 2007; Nancollas et al. 2006; Doga et al. 2002; Anon, 2001; Eastell et al. 1998 ] as evidenced by the recommendation of the ACR and the RCP to use them as first-line therapy [Anon, 2001; Eastell et al. 1998 ]. A listing of the actions of alendronate, risedronate, and zoledronic acid as well as other bisphosphonates to prevent the loss and restoration of BMD in GIO is shown in Table 1 . Oral daily use of alendronate at 10 mg for 48 weeks significantly increased BMD at the lumbar spine and femoral neck, when compared to untreated control patients.
Two-year data show a reduction in the incidence of vertebral fractures (Table 1) . Oral daily use of risedronate, at 5 mg was tested in two placebocontrolled 12-month clinical trials in patients either on long-term glucocorticoid therapy (treatment) or in subjects initiating glucocorticoid treatment (prevention) ( Table 1 ). In the prevention trial, risedronate stabilized BMD, whereas in the treatment trial risedronate increased BMD. Pooled data from the two trials revealed a 70% reduction in the incidence of vertebral fractures as compared to control subjects after 12 months. Recently, zoledronic acid was shown to have a greater effect on BMD than risedronate in both prevention and treatment trials [Reid et al. 2009 ]. The benefits of bisphosphonates in GIO have been ascribed primarily to their antiresorptive activity, although an inhibition of glucocorticoid-induced apoptosis of osteoblasts and osteocytes may contribute to their therapeutic effectiveness [Russell et al. 2008; Doga et al. 2002] . Bisphosphonates are more effective than vitamin D in the prevention of fractures in GIO, a point that does not negate the need for supplemental calcium and vitamin D, along with the bisphosphonate. The superiority of bisphosphonates over other antiresorptive approaches to GIO was supported by a meta-analysis [Amin et al. 2002 ]. An overall reduction in the risk of morphometric radiological vertebral deformities of 37% (relative risk 0.63, 95% confidence interval 0.490.80) was reported with bisphosphonates [Amin et al. 2002] . Anabolic agents were not considered in this analysis. The use of bisphosphonates in eugonadal premenopausal women has to be considered carefully since bisphosphonates may cross the placenta and their potential effects on embryonic development are not known.
Unresolved issues with the use of bisphosphonates in GIO include the mechanism responsible for the increase in BMD, their effects on nonvertebral fractures, the duration of therapy and the incidence of side effects in the context of GIO [Doga et al. 2008] . One report has implicated glucocorticoids as a contributing factor in osteonecrosis of the jaw, associated with intravenous bisphosphonates [Bilezikian, 2006] .
Anabolic therapy
Glucocorticoids have marked inhibitory effects on osteoblastic cell differentiation and function, and as a consequence they inhibit bone formation [Weinstein et al. 1998 ]. Glucocorticoids decrease cell replication and enhance apoptosis of cells of the osteoblastic lineage, thereby reducing the pool of mature osteoblasts [Weinstein et al. 1998 ]. Glucocorticoids also impair osteocytic viability and function [Canalis et al. 1989 ]. Glucocorticoids inhibit the synthesis of insulinlike growth factor (IGF) and oppose Wnt/b-catenin signaling, key regulators of osteoblastic function and osteoblastogenesis [Weinstein et al. 1998 ]. Consequently, an ideal therapy for GIO would reverse the effects of glucocorticoids on osteoblast differentiation, survival, and function.
The anabolic agent, teriparatide should fulfil this need, the data for which are described in the next section. At the time of writing, teriparatide (PTH(1-34)) had not yet been approved for the treatment of GIO by the USA Food and Drug Administration (FDA) but was under review.
Parathyroid hormone
Parathyroid hormone (PTH) is an attractive candidate for the therapy of GIO because it protects against osteoblast apoptosis and increases osteoblast cell numbers and activity [Iu et al. 2005; Jilka et al. 1999; Lane et al. 1998 ]. The use of PTH in GIO has been examined in postmenopausal women with rheumatoid arthritis receiving prednisone and estrogens [Rehman et al. 2003; Lane et al. 2000; . In this population, daily treatment with teriparatide increased vertebral BMD and, more modestly, hip BMD. PTH administration induces an initial increase in bone formation followed by a more gradual increase of bone resorption [Rehman et al. 2003 ]. According to the concept of the 'anabolic window', PTH rapidly stimulates osteoblastic function, followed by stimulation of remodelling.
The remodelling system is associated with an upregulation of osteoblast derived cytokines such as RANKL, IL-6 and a suppression of osteoprotegerin [Canalis et al. 2007b; Buxton et al. 2004] . Effects on remodelling, as opposed to modellingbased actions of teriparatide, are also important in the overall effects of the drug.
Recently, a multicenter, randomized, controlled study was performed to compare the effects of teriparatide with those of alendronate on lumbar spine BMD in patients undergoing long-term glucocorticoid therapy at high risk for osteoporotic fractures that is, with mean baseline lumbar T score of À2.5 and with high prevalence of fragility fractures [Saag et al. 2007] . In this clinical setting, teriparatide was more effective than alendronate in increasing BMD at the lumbar spine and total hip during an 18-month period. Similar results were obtained after 36 months of therapy [Saag et al. 2008] . A secondary endpoint of the study was the reduction of new vertebral fractures after 18 months 6.1% patients receiving alendronate suffered vertebral fractures, whereas the incidence was only 0.6% in the teriparatide arm. This beneficial result of teriparatide therapy over alendronate was sustained after 36 months [Saag et al. 2008] . Teriparatide treatment was associated with injection-site reactions, headache, and dizziness [Saag et al. 2007 ].
Unresolved issues with the use of teriparatide and other forms of PTH in GIO are its use in the prevention of GIO, its use in patients who are resistant to bisphosphonate therapy, its use in younger populations and whether teriparatide should be followed by antiresorptives in GIO, as it is recommended in postmenopausal osteoporosis [Doga et al. 2008; Black et al. 2005] .
Growth hormone
Glucocorticoids decrease the skeletal production of insulin-like growth factor-1 (IGF-1) and exert negative effects on growth hormone (GH) secretion [Mazziotti et al. 2006 ]. Glucocorticoids cause a state of 'functional GH deficiency' by increasing the somatostatin tone in the hypothalamus and reducing the GH response to GH-releasing hormone Veldhuis, 1998, Giustina et al 1992] . GH deficiency may contribute to GIO [Giustina et al. 2008 ]. Consequently, GH or IGF-I administration could revert some of the negative effects of chronic glucocorticoids on the skeleton . However, glucocorticoids decrease the activity of GH on skeletal cells and there are no controlled trials to determine the effectiveness of either GH or IGF-I as treatments for GIO. Increases in serum osteocalcin, carboxyterminal propeptide of type-I procollagen and carboxy-terminal telopeptide of type-I collagen are observed following short-term use of recombinant human GH treatment in a selected population of patients receiving chronic corticosteroid treatment for non-endocrine diseases [Giustina et al. 1995] .
Combined therapy of GH and IGF-I counteracts selected negative effects of glucocorticoids on bone in healthy volunteers, receiving short-term glucocorticoid therapy [Berneis et al. 1999] .
Observational and controlled studies in children receiving glucocorticoid therapy for juvenile idiopathic arthritis demonstrated that GH restored normal height velocity with a concomitant enhancement of bone mineralization [Simon et al. 2007; Bechtold et al. 2005 Bechtold et al. , 2004 Simon et al. 2003 ]. However, the efficacy and safety of GH and IGF-I treatment in GIO is unknown and well-designed prospective controlled studies are necessary before their use can be recommended. use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebocontrolled trials. J Clin Endocrinol Metab 91: 20112016. Van Beek, E., Lowik, C., Que, I. and Papapoulos, S. (1996) Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 11: 14921497.
Conclusion
Van Staa, T.P., Geusens, P., Zhang, B., Leufkens, H.G., Boonen, A. and Cooper, C. (2007) Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatology (Oxford) 46: 460466.
Weinstein, R.S., Jilka, R.L., Parfitt, A.M. and Manolagas, S.C. (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274282.
